Priya Rastogi, MD

Titles and Affiliations

Associate Professor of Medicine
Chief Executive Officer and Chief Medical Officer
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation

Research Area

Improving treatments and quality of life for premenopausal patients with hormone receptor-positive breast cancer

Impact

The standard of care for premenopausal patients with hormone receptor (HR)-positive breast cancer at high risk of recurrence is ovarian function suppression (OFS) and endocrine therapy (ET). Chemotherapy is also given to patients, but its benefit is unclear when used in addition to OFS and ET. The OFSET Trial, expected to enroll nearly 4000 patients, seeks to evaluate the benefits of using chemotherapy in addition to OFS and ET. Through a trial sub-study, Dr. Rastogi and her team are developing a patient engagement web portal that will provide trial participants active support for symptom management and adherence to ET.

Progress Thus Far

The OFSET trial began recruiting patients in early 2024. The research team has developed the materials for the patient engagement web portal. They hypothesize that those trial participants who actively use the portal will have greater adherence to ET.

What’s Next

In the coming year, the sub-study protocol will be finalized and activated as a part of the OFSET trial. Dr. Rastogi and her team will provide training at clinical sites on how to enroll patients in the sub-study.

Biography

Priya Rastogi, MD is an Associate Professor of Medicine at the University of Pittsburgh, School of Medicine, and a medical oncologist at Magee-Womens Hospital of UPMC. She is also the CEO/CMO, NSABP Foundation and on the NRG Oncology Board of Directors.

Her clinical research interests include Phase II and Phase III neoadjuvant and adjuvant breast cancer clinical trials. She has been involved with the development and implementation of clinical trials through NRG Oncology and the NSABP Foundation. Dr. Rastogi has published on breast cancer in the New England Journal of Medicine and the Journal of Clinical Oncology. She serves on the NRG Oncology Breast Committee and NRG Working Group. She is Co-Chair of the NRG New Investigator Committee.